New drug combo aims to shrink tumors in advanced colorectal cancer
NCT ID NCT07585279
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new form of chemotherapy (liposomal irinotecan) combined with other drugs works better than standard irinotecan for people with metastatic colorectal cancer that has progressed after first-line treatment. About 408 adults aged 18 to 75 will be randomly assigned to one of three treatment groups. The goal is to see if the new combination shrinks tumors and improves survival, while also checking safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••